Despite the great successes achieved in the fields of virology and diagnostics, several
difficulties affect improvements in hepatitis C virus (HCV) infection control and eradication in …

Despite major advances in the understanding and treatment of hepatitis C, a preventive
vaccine remains elusive. The marked genetic diversity and multiple mechanisms of …

Currently, no vaccine exists for hepatitis C virus (HCV), a major pathogen thought to infect
170 million people globally. Many studies suggest that host T cell responses are critical for …

Nanotechnology has emerged as a transformative pathway in vaccine research and
delivery. Nanovaccines, encompassing lipid and nonlipid formulations, exhibit considerable …

Hepatitis C virus (HCV) infects an estimated more than 150 million people and is a leading
cause of liver disease worldwide. The development of direct-acting antivirals (DAAs) will …

Abstract Background Although DAAs hold promise to significantly reduce rates of chronic
HCV infections, its eradication still requires development of an effective vaccine. Prolonged …

The highly attenuated poxvirus strain modified vaccinia virus Ankara (MVA) has reached
maturity as a vector delivery system and as a vaccine candidate against a broad spectrum of …

Adenoviral vectors encoding hepatitis C virus (HCV) nonstructural (NS) proteins induce
multispecific, high‐magnitude, durable CD4+ and CD8+ T‐cell responses in healthy …

Hepatitis C virus (HCV) infection is still a major public health problem worldwide since its
first identification in 1989. At the start, HCV infection was post-transfusion viral infection …

Clearance of infections caused by the hepatitis C virus (HCV) correlates with HCV-specific T
cell function. We therefore evaluated therapeutic vaccination in 12 patients with chronic HCV …